IPSEN (OTCMKTS:IPSEY) Stock Crosses Above 200 Day Moving Average – Here’s What Happened

IPSEN (OTCMKTS:IPSEY) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $38.24 and traded as high as $44.0080. IPSEN shares last traded at $44.0080, with a volume of 245 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IPSEY shares. UBS Group lowered shares of IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a report on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

IPSEN Stock Performance

The stock’s fifty day simple moving average is $43.58 and its 200-day simple moving average is $38.24.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).